Kestra Medical holder plans 15,000-share sale

A notice by Brian Webster covers 15,000 shares of Kestra Medical Technologies, Ltd. common stock for potential sale, with a value of 336,609.41.

Rhea-AI Filing Summary

A notice by Brian Webster covers 15,000 shares of Kestra Medical Technologies, Ltd. common stock for potential sale, with a value of 336,609.41. Merrill Lynch, 225 Liberty St Floor 37, New York, NY 10281, and Nasdaq are listed in connection with this transaction. The shares were acquired on 01/01/2026 via a restricted share issuance granted as part of the issuer’s equity compensation plan.

The disclosure also lists three prior sales of 15,000 common shares each on 04/15/2026, 05/15/2026 and 06/15/2026, with reported values of 300,671.04, 314,329.85 and 312,142.94, respectively.

Key Figures

Shares covered for potential sale: 15000 shares Value of shares covered for sale: 336609.41 Shares sold on 04/15/2026: 15000 shares for 300671.04 +3 more

6 metrics

Shares covered for potential sale 15000 shares Common Stock in 144: Securities Information

Value of shares covered for sale 336609.41 Associated with 15000 Common Stock entry

Shares sold on 04/15/2026 15000 shares for 300671.04 Securities Sold During The Past 3 Months

Shares sold on 05/15/2026 15000 shares for 314329.85 Securities Sold During The Past 3 Months

Shares sold on 06/15/2026 15000 shares for 312142.94 Securities Sold During The Past 3 Months

Acquisition date of shares 01/01/2026 Date tied to Restricted Share Issuance

Key Terms

Restricted Share Issuance, equity compensation plan, Securities Sold During The Past 3 Months

3 terms

Restricted Share Issuance financial

"Common Stock | 01/01/2026 | Restricted Share Issuance | KESTRA"

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock transaction involving KMTS does Brian Webster’s notice cover?

The notice covers 15,000 shares of Kestra Medical Technologies, Ltd. common stock for potential sale, associated with a value of 336,609.41. Merrill Lynch and Nasdaq are listed in connection with this planned transaction.

How were the KMTS shares in Brian Webster’s planned sale originally acquired?

The 15,000 Kestra Medical shares were acquired on 01/01/2026 through a Restricted Share Issuance. They were granted as part of the issuer equity compensation plan, according to the disclosure details.

Which broker and market are associated with the KMTS shares in this notice?

The entry lists Merrill Lynch, 225 Liberty St Floor 37, New York, NY 10281 alongside the Kestra Medical common stock. Nasdaq is also identified in the same securities information section.

What prior KMTS share sales by Brian Webster are disclosed for the past three months?

Three earlier transactions each involve 15,000 common shares: on 04/15/2026 for 300,671.04, on 05/15/2026 for 314,329.85, and on 06/15/2026 for 312,142.94. All are listed as securities sold during the past three months.

What type of securities are involved in Brian Webster’s KMTS transactions?

All transactions involve Kestra Medical equity: Common Stock or Common Shares. The main planned transaction covers 15,000 Kestra Medical common shares, and each of the three prior monthly sales also involves 15,000 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 04:20 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001877188
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KESTRA MEDICAL TECHNOLOGIES, LTD.
SEC File Number	001-42549
Address of Issuer	3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WASHINGTON 98033
Phone	(425) 279-8002
Name of Person for Whose Account the Securities are To Be Sold	Webster Brian Daniel
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	15000	336609.41	58602497	07/15/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/01/2026	Restricted Share Issuance	KESTRA MEDICAL TECHNOLOGIES, LTD.			15000	01/01/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	04/15/2026	15000	300671.04
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	05/15/2026	15000	314329.85
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 Common Shares WA 98033	Common Shares	06/15/2026	15000	312142.94

144: Remarks and Signature

Remarks
Date of Notice	07/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Brian Webster
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)